1 Introduction 6

• 1.1 Industry Definition and Research Scope 6
  • 1.1.1 Industry Definition 6
  • 1.1.2 Research Scope 7
• 1.2 Research Methodology 10
  • 1.2.1 Overview of Market Research Methodology 10
  • 1.2.2 Market Assumption 11
  • 1.2.3 Secondary Data 11
  • 1.2.4 Primary Data 11
  • 1.2.5 Data Filtration and Model Design 12
  • 1.2.6 Market Size/Share Estimation 13
  • 1.2.7 Research Limitations 14
• 1.3 Executive Summary 15

2 Market Overview and Dynamics 17

• 2.1 Market Size and Forecast 17
  • 2.1.1 Impact of COVID-19 on World Economy 18
  • 2.1.2 Impact of COVID-19 on the Market 20
• 2.2 Major Growth Drivers 22
• 2.3 Market Restraints and Challenges 26
• 2.4 Emerging Opportunities and Market Trends 29
• 2.5 Porter’s Fiver Forces Analysis 33

3 Segmentation of Asia Pacific Market by Product 37

• 3.1 Market Overview by Product 37
• 3.2 Hemostatic Agents 39
• 3.3 Bone-graft Substitutes 40
  • 3.2.1 Synthetic Graft Extender 41
  • 3.2.2 Demineralized Bone Matrix 42
  • 3.2.3 Bone Morphogenetic Proteins 43
  • 3.2.4 Cell-Based Matrices 44
• 3.4 Surgical Sealants and Adhesives 45
  • 3.4.1 Natural Surgical Sealing Agents 46
  • 3.4.2 Synthetic Surgical Sealing Agents 47
• 3.5 Soft-tissue Attachments 48
  • 3.5.1 Natural & Biological Mesh/Patch 49
  • 3.5.2 Synthetic Mesh/Patch 50
• 3.6 Adhesion Barriers 51
  • 3.6.1 Natural Adhesion Barriers 52
  • 3.6.2 Synthetic Adhesion Barriers 53
• 3.7 Staple Line Reinforcement 54

4 Segmentation of Asia Pacific Market by Source Type 55

• 4.1 Market Overview by Source Type 55
• 4.2 Natural/Biological Products 57
• 4.3 Synthetic Products 58

5 Segmentation of Asia Pacific Market by Application 60

• 5.1 Market Overview by Application 60
• 5.2 Orthopedic Surgery 62
• 5.3 General Surgery 63
• 5.4 Neurological Surgery 64
• 5.5 Cardiovascular Surgery 65
• 5.6 Gynecological Surgery 66
• 5.7 Other Applications 67

6 Asia-Pacific Market 2020-2027 by Country 68

• 6.1 Overview of Asia-Pacific Market 68
• 6.2 China 71
• 6.3 Japan 73
• 6.4 India 76
• 6.5 Australia 78
• 6.6 South Korea 80
• 6.7 Rest of APAC Region 82

7 Competitive Landscape 84

• 7.1 Overview of Key Vendors 84
• 7.2 New Product Launch, Partnership, Investment, and M&A 87
• 7.3 Company Profiles 88

B. Braun Melsungen AG 88

Baxter International, Inc. 90

Becton, Dickinson and Company (C.R. Bard) 91

Betatech Medical 92

CryoLife Inc. 93

CSL Limited 94

Hemostasis LLC 95

Integra Lifesciences Holdings Corporation 96

Johnson & Johnson 97

Medtronic PLC 98

Pfizer, Inc. 99

Sanofi S.A. 100

Stryker Corporation 101

RELATED REPORTS 102

Asia Pacific biosurgery market will grow by 8.9% annually with a total addressable market cap of $33.2 billion over 2021-2027 owing to the growth in joint reconstruction and spinal fusion, the increasing number of surgeries especially minimally invasive surgeries due to lifestyle disorders and the rise in the overweight & aging population.
Highlighted with 31 tables and 49 figures, this 102-page report “Asia Pacific Biosurgery Market 2020-2027 by Product, Source Type (Natural, Synthetic), Application (Orthopedic, General, Neurological, Cardiovascular), and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific biosurgery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biosurgery market in every aspect of the classification from perspectives of Product, Source Type, Application, and Country.

Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hemostatic Agents
• Bone-graft Substitutes
o Synthetic Graft Extender
o Demineralized Bone Matrix
o Bone Morphogenetic Proteins
o Cell-Based Matrices
• Surgical Sealants and Adhesives
o Natural Surgical Sealing Agents
o Synthetic Surgical Sealing Agents
• Soft-tissue Attachments
o Natural & Biological Mesh/Patch
o Synthetic Mesh/Patch
• Adhesion Barriers
o Natural Adhesion Barriers
o Synthetic Adhesion Barriers
• Staple Line Reinforcement

Based on Source Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Natural/Biological Products
• Synthetic Products

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Gynecological Surgery
• Other Applications

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Product, Source Type, and Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
B. Braun Melsungen AG
Baxter International, Inc.
Becton, Dickinson and Company (C.R. Bard)
Betatech Medical
CryoLife Inc.
CSL Limited
Hemostasis LLC
Integra Lifesciences Holdings Corporation
Johnson & Johnson
Medtronic PLC
Pfizer, Inc.
Sanofi S.A.
Stryker Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)